Global Cord Blood Return on Equity

Global Cord Blood (CORBF) currently reports a ROE of 61.43%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Global Cord Blood's ROE history and peer comparisons.

Global Cord Blood's ROE of 61.43% is higher than the Healthcare sector average of -75.59%. That is roughly 181.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Global Cord Blood's current 61.43% should be judged against Healthcare norms (sector average: -75.59%) and against CORBF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 61.43%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Global Cord Blood, and consider following CORBF for alerts when major investors trade the stock.

Global Cord Blood is classified in the Healthcare sector. On ROE, it currently shows 61.43% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CORBF with unrelated industries.